Condition (MeSH)
Diabetes Mellitus, Lipoatrophic
ClinicalTrials.gov lists 31 trials for Diabetes Mellitus, Lipoatrophic or a narrower condition beneath it. Takeda has the most among industry and government lead sponsors, with 27.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
31 of the 31 trials are tagged with Diabetes Mellitus, Lipoatrophic itself; the rest are tagged with a narrower condition beneath it.
When did Diabetes Mellitus, Lipoatrophic trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2009 | 1 |
| 2008 | 3 |
| 2007 | 6 |
| 2006 | 3 |
| 2005 | 1 |
| 2004 | 3 |
| 2003 | 7 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Diabetes Mellitus, Lipoatrophic trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 8 |
| Phase 3 | 18 |
| Phase 4 | 4 |
| Observational | 1 |
How many Diabetes Mellitus, Lipoatrophic trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 21 |
| Terminated | 8 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Diabetes Mellitus, Lipoatrophic trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Takeda | 27 |
| Kobe University | 2 |
| Akcea Therapeutics | 1 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
Which drugs are being tested for Diabetes Mellitus, Lipoatrophic? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| TAK-559 | 3 |
| Alogliptin Benzoate | 3 |
| Glyburide | 3 |
| Trelagliptin | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pioglitazone - TZD | 10 |
| Pioglitazone and Metformin | 6 |
| 1% Metformin | 5 |
| Add Glimepiride | 3 |
| Pioglitazone and insulin | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Diabetes Mellitus, Lipoatrophic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Coronary Artery Disease | 36 | 1 |
| Non-Cardia Chest Pain | 20 | 1 |
| Angina Pectoris | 12 | 1 |
| Coronary Artery Stenosis | 10 | 1 |
| Cardiac Failure Congestive | 8 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Diabetes Mellitus, Lipoatrophic? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Lipoatrophy revisited. | Trends in endocrinology and metabolism: TEM | 2000 | Yes |
| Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. | Diabetes | 1998 | Yes |
| Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. | Lancet (London, England) | 1999 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.